The NAD+ Supplement Stack Is Getting Crowded. Here's What the Evidence Actually Supports.

You're 44, your bloodwork looks fine, and you've started noticing the gap between how you feel at 9 a.m. versus 3 p.m. Someone in your running group mentions they're taking NMN. Your functional medicine doc mentions NR. You've seen IV NAD+ clinics opening in your neighbourhood, charging $300 a session. Before you commit to any of it, you should understand what's actually been tested, what doses were used, and where the commercial landscape is running well ahead of the science.

What NAD+ Decline Actually Looks Like

Cellular NAD+ (nicotinamide adenine dinucleotide) levels fall measurably with age. A 2023 analysis published by Shade in Integrative Medicine: A Clinician's Journal put the decline at roughly 50% between a person's 40s and 60s, which tracks with earlier tissue-sample data from Zhu et al. (2015) showing similar drops in human skeletal muscle. The functional consequence is reduced activity of sirtuins and PARP enzymes — both implicated in DNA repair and mitochondrial regulation. That much is settled biology. What's less settled is whether oral precursor supplementation meaningfully reverses that decline in humans at the tissue level, rather than just in the blood.

The distinction matters. Most human trials measure NAD+ in whole blood or peripheral blood mononuclear cells because those samples are accessible. Whether that correlates with intracellular concentrations in muscle, liver, or brain is a separate question that hasn't been answered with large-scale tissue biopsy data.

NMN vs. NR: The Precursor Race

The two main commercially available precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — take different enzymatic routes to NAD+. Neither has a decisive clinical advantage proven in humans yet.

NR has more published human data. A randomised, double-blind trial by Dollerup et al. (2018) in Nature Communications dosed obese men at 2,000 mg/day for 12 weeks and found statistically significant increases in blood NAD+ metabolites but no significant changes in insulin sensitivity, blood pressure, or body composition. The sample was 40 participants — informative but not definitive.

NMN human data has been slower to accumulate. A 2021 trial by Yoshino et al. in Science (n=25 postmenopausal women with prediabetes) showed 250 mg/day over 10 weeks improved muscle insulin signalling without affecting other metabolic markers. A specific population, a specific outcome, modest numbers.

Retail pricing in mid-2026 reflects the hype more than the evidence differential. Quality NR products — including Tru Niagen (300 mg/day) and Elysium Basis — run $60–$90 for a 30-day supply. NMN at comparable duration runs $70–$120 depending on dose and brand, with products like ProHealth Longevity and DoNotAge at the higher end of that range. Neither delivers an effect size that has been quantified against those price points.

Where IV NAD+ Sits in the Market

The IV delivery route bypasses gut absorption entirely and raises blood NAD+ levels acutely — that part is pharmacologically real. What IV clinics don't always communicate clearly is that a single infusion of 500–750 mg NAD+ typically produces a transient spike that normalises within days without consistent follow-up doses. Session pricing in major US cities currently ranges from $250 to $600, and most clinic protocols recommend 4–10 sessions for initial loading, putting starting costs between $1,000 and $6,000 before any maintenance schedule.

For structured programmes that combine NAD+ with broader longevity protocols, System Labs and Yucca Health are among the telehealth platforms that have integrated precursor supplementation into longer-term monitoring frameworks — a different model than walk-in IV bars, and worth evaluating on those terms. For in-person options, the concentration of longevity clinics in Los Angeles means you can compare approaches across a relatively dense market.

The Resveratrol and Fisetin Add-On Problem

The supplement industry has layered NAD+ into broader longevity stacks alongside resveratrol, pterostilbene, fisetin, and quercetin — compounds with credible mechanistic rationale (particularly as sirtuin activators or senolytic agents) but thin human clinical data. Resveratrol's bioavailability in standard oral form is notoriously poor; Walle et al. (2004) in Annals of the New York Academy of Sciences estimated intestinal absorption at roughly 70%, but hepatic first-pass metabolism reduces systemic availability dramatically, leaving plasma concentrations well below those used in cell studies. Products bundling these compounds — Qualia Longevity and Life Extension's Senolytic Activator are two prominent examples — are selling theoretical synergy, not demonstrated additive effect.

This is the segment of the market most deserving of scepticism. Stacking compounds with complementary mechanisms makes biological sense as a hypothesis. Charging $150–$180 per month for a pre-assembled stack based on that hypothesis is marketing, not medicine.

What Monitoring Actually Makes Sense

Supplementing without tracking any biomarkers means you have no way to confirm an effect or catch a problem. Baseline and follow-up testing worth considering includes whole-blood NAD+ (some labs now offer this as a standalone panel for $80–$150), fasting insulin, hsCRP, and a standard metabolic panel. Some online longevity programs include quarterly biomarker reviews as part of their structure, which changes the cost calculus considerably compared to paying for supplements and labs separately.

There's also a practical safety reason to monitor: high-dose niacin-pathway supplementation at NR or NMN doses above 1,000 mg/day has been associated with elevated homocysteine in some individuals, per a 2023 observation from Dellinger et al. in Nature Metabolism. If you're running doses in that range, checking methylation markers — specifically homocysteine and methylmalonic acid — is basic pharmacovigilance, not overcaution.

The Honest Takeaway

The biology underlying NAD+ supplementation is among the more credible in the longevity space. The human clinical evidence, as of mid-2026, supports the conclusion that oral precursors raise circulating NAD+ metabolites at doses of 250–500 mg/day. What those increases do to long-term health outcomes in non-diseased adults remains untested at scale. The clinics and products most worth your money are the ones that say exactly that, build in measurement, and don't promise you'll feel 30 again. The ones selling IV rejuvenation protocols at $4,000 upfront — without baseline labs or follow-up panels — are pricing certainty they don't have.

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---